Changes in plasma levels of cholecystokinin, neurotensin, VIP and PYY in gastric and colorectal cancer – Preliminary results

Peptides ◽  
2019 ◽  
Vol 122 ◽  
pp. 170148 ◽  
Author(s):  
Aneta Lidia Zygulska ◽  
Agata Furgala ◽  
Jolanta Kaszuba-Zwoińska ◽  
Krzysztof Krzemieniecki ◽  
Krzysztof Gil
Keyword(s):  
Colorectal Cancer ◽  
Plasma Levels ◽  
Preliminary Results

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type

36P Plasma levels of hsa_circ_0001445 and hsa_circ_0007915 may indicate the presence of metastatic disease in patients with colorectal cancer

2021 ◽  
Vol 32 ◽  
pp. S1356-S1357
Author(s):  
M. Radanova ◽  
G. Mihaylova ◽  
O. Tasinov ◽  
D. Ivanova ◽  
N. Nazifova-Tasinova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Disease ◽  
Plasma Levels

scholarly journals Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

Metabolites ◽  
2018 ◽  
Vol 8 (4) ◽  
pp. 91 ◽  
Author(s):  
Paul Wood ◽  
Michelle Donohue ◽  
John Cebak ◽  
Taylor Beckmann ◽  
Márcia Messias ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dicarboxylic Acid ◽  
Cancer Patients ◽  
Plasma Levels ◽  
High Resolution Mass Spectrometry ◽  
Sporadic Colorectal Cancer ◽  
Inherited Susceptibility ◽  
Potential Biomarker ◽  
Colorectal Cancer Patients ◽  
Long Chain

Background: There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Methods: Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian [n = 62] and Brazilian [n = 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP; n = 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer. Results: Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual’s age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients. Conclusions: The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders.

Sign in / Sign up

Export Citation Format

Share Document